Literature DB >> 27050475

Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: The OPUS study.

Sara Bergh1, Carsten Hjorthøj2, Holger J Sørensen2, Birgitte Fagerlund3, Stephen Austin2, Rikke Gry Secher2, Jens Richardt Jepsen4, Merete Nordentoft2.   

Abstract

BACKGROUND: Identifying baseline predictors of the long-term course of cognitive functioning in schizophrenia spectrum disorders is important because of associations between cognitive functioning (CF) and functional outcome. Determining whether CF remains stable or change during the course of illness is another matter of interest.
METHODS: Participants from The Danish OPUS Trial, aged 18-45years, with a baseline ICD-10 schizophrenia spectrum diagnosis, were assessed on psychopathology, social and vocational functioning at baseline, and cognitive functioning 5 (N=298) and 10years (N=322) after baseline. Uni- and multi-variable regression analyses of potential baseline predictors of 10-year CF were performed. Also, changes in CF and symptomatology between 5 and 10years of follow-up were assessed.
FINDINGS: Baseline predictors of impaired CF after 10years included male gender, unemployment, poor premorbid achievement and later age of onset. Having finished high school and receiving early intervention treatment was associated with better CF. Age, growing up with both parents, number of family and friends, primary caregivers education, premorbid social function, negative symptoms, GAF (symptoms, function) and substance abuse, were associated with CF in univariable analyses. Non-participants generally suffered from more severe dysfunction. Longitudinally, amelioration in negative symptoms was associated with improved speed of processing and executive functions. Symptom scores generally improved with time, while scores for all cognitive tests remained stable.
CONCLUSION: The current study identifies several robust associations between baseline characteristics and 10-year cognitive outcome. Several other variables were univariably associated with 10-year cognitive outcome. Also, we found evidence for stability of CF over time.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brief Assessment of Cognition in Schizophrenia (BACS); Cognition; Cognitive stability; First-episode psychosis; Longitudinal; Predictors

Mesh:

Year:  2016        PMID: 27050475     DOI: 10.1016/j.schres.2016.03.025

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

1.  Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging.

Authors:  Leticia Sanguinetti Czepielewski; Raffael Massuda; Bruna Panizzutti; Lucas Kich Grun; Florencia María Barbé-Tuana; Antonio Lucio Teixeira; Deanna M Barch; Clarissa S Gama
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

2.  Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.

Authors:  Ezequiel Uribe; Leticia Fernández; Dulce Pacheco; Luis Fernandez; Nieves Nayadoleni; Antonio Eblen-Zajjur
Journal:  J Neural Transm (Vienna)       Date:  2019-05-02       Impact factor: 3.575

3.  Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis.

Authors:  Philippe Conus; Sue Cotton; Benno G Schimmelmann; Patrick D McGorry; Martin Lambert
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-05-05       Impact factor: 4.328

4.  Hyper- and Hypomentalizing in Patients with First-Episode Schizophrenia: fMRI and Behavioral Studies.

Authors:  Vibeke Bliksted; Chris Frith; Poul Videbech; Birgitte Fagerlund; Charlotte Emborg; Arndis Simonsen; Andreas Roepstorff; Daniel Campbell-Meiklejohn
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

5.  Use of Chronic Care Management Codes for Medicare Beneficiaries: a Missed Opportunity?

Authors:  Rebekah L Gardner; Rouba Youssef; Blake Morphis; Alyssa DaCunha; Kimberly Pelland; Emily Cooper
Journal:  J Gen Intern Med       Date:  2018-07-20       Impact factor: 5.128

6.  Association of Age at Onset and Longitudinal Course of Prefrontal Function in Youth With Schizophrenia.

Authors:  Tara A Niendam; Kimberly L Ray; Ana-Maria Iosif; Tyler A Lesh; Stefania R Ashby; Pooja K Patel; Jason Smucny; Emilio Ferrer; Marjorie Solomon; J Daniel Ragland; Cameron S Carter
Journal:  JAMA Psychiatry       Date:  2018-12-01       Impact factor: 21.596

7.  Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study.

Authors:  A M Sánchez-Torres; L Moreno-Izco; R Lorente-Omeñaca; B Cabrera; A Lobo; A M González-Pinto; J Merchán-Naranjo; I Corripio; E Vieta; E de la Serna; A Butjosa; F Contreras; S Sarró; G Mezquida; M Ribeiro; M Bernardo; M J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-21       Impact factor: 5.270

Review 8.  Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective.

Authors:  Julia M Sheffield; Nicole R Karcher; Deanna M Barch
Journal:  Neuropsychol Rev       Date:  2018-10-20       Impact factor: 7.444

9.  Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders: Findings From the Suffolk County Mental Health Project.

Authors:  Anne-Kathrin J Fett; Eva Velthorst; Abraham Reichenberg; Camilo J Ruggero; Jennifer L Callahan; Laura J Fochtmann; Gabrielle A Carlson; Greg Perlman; Evelyn J Bromet; Roman Kotov
Journal:  JAMA Psychiatry       Date:  2020-04-01       Impact factor: 21.596

10.  Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals.

Authors:  Luccas S Coutinho; Hianna Honorato; Cinthia H Higuchi; Daniel A Cavalcante; Sintia Belangeiro; Mariane Noto; Rodrigo A Bressan; Quirino Cordeiro; Cristiano Noto; Ary Gadelha
Journal:  Schizophr Res Cogn       Date:  2018-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.